Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.2 USD | +1.00% | +0.53% | -9.58% |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.58% | 1.79B | C- | ||
-3.93% | 86.16B | A- | ||
+2.76% | 40.17B | A- | ||
-16.48% | 31.47B | B- | ||
+55.13% | 25.24B | A | ||
-13.58% | 15.82B | C | ||
-9.12% | 11.96B | D+ | ||
-42.56% | 11.61B | B | ||
+6.14% | 8.84B | B+ | ||
-2.11% | 7.93B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CPRX Stock
- Ratings Catalyst Pharmaceuticals, Inc.